Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRANASDAQ:CYCNNASDAQ:HCWBOTCMKTS:TDLAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.32-3.2%$3.60$1.93▼$10.16$8.45M0.34278,131 shs8,729 shsCYCNCyclerion Therapeutics$3.10+3.0%$3.00$1.27▼$9.47$9.95M1.581.28 million shs16,196 shsHCWBHCW Biologics$5.50+5.4%$7.66$5.00▼$100.80$7.91M0.83262,540 shs54,567 shsTDLAFTBG Diagnostics$0.04-14.0%$0.04$0.01▼$0.13$2.38M-12.386,655 shs3,200 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica0.00%+7.52%-3.38%-25.11%-26.08%CYCNCyclerion Therapeutics-0.48%-0.16%-3.55%+26.52%+37.67%HCWBHCW Biologics-4.92%-14.98%+0.19%-60.97%-87.80%TDLAFTBG Diagnostics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica0.335 of 5 stars0.03.00.00.02.10.80.0CYCNCyclerion Therapeutics1.9134 of 5 stars0.03.00.00.03.83.30.6HCWBHCW Biologics3.5717 of 5 stars3.55.00.00.03.43.30.0TDLAFTBG DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/ACYCNCyclerion Therapeutics 0.00N/AN/AN/AHCWBHCW Biologics 3.00Buy$35.00536.36% UpsideTDLAFTBG Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TDLAF, CYCN, BMRA, and HCWB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.68M1.49N/AN/A$0.39 per share8.51CYCNCyclerion Therapeutics$2.08M4.78N/AN/A$4.62 per share0.67HCWBHCW Biologics$1.45M5.48N/AN/A$0.37 per share14.86TDLAFTBG Diagnostics$2.33M1.02N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-100.52%-90.19%-64.54%8/26/2025 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$1.16N/A∞N/AN/A-55.32%-48.35%8/5/2025 (Estimated)HCWBHCW Biologics-$24.99M-$23.25N/A∞N/A-1,067.82%-2,516.84%-132.95%N/ATDLAFTBG Diagnostics$530KN/A0.00∞N/AN/AN/AN/AN/ALatest TDLAF, CYCN, BMRA, and HCWB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A4/14/2025Q3 2025BMRABiomericaN/A-$0.48N/A-$0.06N/A$1.12 million3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ATDLAFTBG DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.172.22CYCNCyclerion TherapeuticsN/A5.075.07HCWBHCW BiologicsN/A0.070.07TDLAFTBG DiagnosticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%CYCNCyclerion Therapeutics75.62%HCWBHCW Biologics2.96%TDLAFTBG DiagnosticsN/AInsider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%CYCNCyclerion Therapeutics34.30%HCWBHCW Biologics42.70%TDLAFTBG Diagnostics3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million15.59 millionOptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataHCWBHCW Biologics401.44 million22.32 millionNot OptionableTDLAFTBG DiagnosticsN/A55.29 millionN/ANot OptionableTDLAF, CYCN, BMRA, and HCWB HeadlinesRecent News About These CompaniesGrapevines: Napa Valley College launches Regional Transportation, Distribution & Logistic (TDL) training programJanuary 15, 2022 | napavalleyregister.comCurtiss-Wright Updates TDL Software Products in Advance of DoD’s Link 16 Cryptographic Modernization Capability MandateJanuary 8, 2022 | newswiretoday.comGlobal Tunable Diode Laser (TDL) Analyzers Market Growth 2021-2026January 7, 2022 | reportsnreports.comGlobal and United States Tunable Diode Laser (TDL) Gas Analyzers Market Insights, Forecast to 2027December 23, 2021 | reportsnreports.comTDL: Week 10 Thursday scores and highlightsNovember 5, 2021 | kplctv.comRaiders Podcast: TDL Ruggs reaction and mailbagNovember 4, 2021 | msn.comTDL: Week 8 Thursday scores and highlightsOctober 22, 2021 | kplctv.comRaiders podcast: TDL Week 6 review vs. The BroncosOctober 20, 2021 | msn.comTDL: Week 7 Thursday scores and highlightsOctober 15, 2021 | kplctv.comTDL: Week 6 Thursday scores and highlightsOctober 8, 2021 | kplctv.comTDL Thursday scores and highlightsSeptember 24, 2021 | kplctv.comTBG Diagnostics Ltd.August 20, 2021 | barrons.comTDL Two-A-Days high school football previews scheduleAugust 10, 2021 | kplctv.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTDLAF, CYCN, BMRA, and HCWB Company DescriptionsBiomerica NASDAQ:BMRA$3.32 -0.11 (-3.21%) As of 03:03 PM EasternBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Cyclerion Therapeutics NASDAQ:CYCN$3.10 +0.09 (+2.99%) As of 03:47 PM EasternCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.HCW Biologics NASDAQ:HCWB$5.50 +0.28 (+5.36%) As of 04:00 PM EasternHCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.TBG Diagnostics OTCMKTS:TDLAF$0.04 -0.01 (-14.00%) As of 09/7/2021TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
